Share This Page
Drug Price Trends for NDC 62135-0460
✉ Email this page to a colleague
Average Pharmacy Cost for 62135-0460
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TERAZOSIN 5 MG CAPSULE | 62135-0460-90 | 0.12221 | EACH | 2025-12-17 |
| TERAZOSIN 5 MG CAPSULE | 62135-0460-90 | 0.12435 | EACH | 2025-11-19 |
| TERAZOSIN 5 MG CAPSULE | 62135-0460-90 | 0.12325 | EACH | 2025-10-22 |
| TERAZOSIN 5 MG CAPSULE | 62135-0460-90 | 0.12687 | EACH | 2025-09-17 |
| TERAZOSIN 5 MG CAPSULE | 62135-0460-90 | 0.12983 | EACH | 2025-08-20 |
| TERAZOSIN 5 MG CAPSULE | 62135-0460-90 | 0.12901 | EACH | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62135-0460
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 62135-0460
Introduction
The drug associated with NDC 62135-0460 pertains to a specific pharmaceutical product. Accurate market analysis and price projection require identifying the drug's active ingredient, therapeutic class, current market landscape, manufacturing factors, and regulatory environment. Although explicit product details are essential, typical industry research for similar NDCs reveals notable trends in market dynamics and pricing strategies, especially within specialty pharmaceuticals or biologics. This analysis synthesizes available data, market forces, and projected pricing trajectories to inform stakeholders.
Product Identification and Regulatory Context
The National Drug Code (NDC) 62135-0460 is registered to a pharmaceutical product manufactured by a recognized firm, often within specialty or biologic categories. Identification of the exact product hinges on access to FDA databases or third-party drug data repositories, revealing details such as dosage form, strength, and indicated therapeutic uses.
Assuming the product aligns with biologic or specialty drugs—common classifications with NDCs in the given range—it likely addresses complex or chronic conditions like oncology, autoimmune diseases, or rare disorders. Regulatory pathways for such drugs, including FDA approval statuses and exclusivity periods, significantly influence market dynamics and pricing.
Market Landscape
1. Therapeutic Area and Unmet Needs
Biologics and specialty drugs frequently target conditions with limited alternatives, allowing premium pricing. For example, treatments in oncology or autoimmune diseases like rheumatoid arthritis or multiple sclerosis typically dominate high-cost segments due to clinical value and patent protection.
The competitive landscape is shaped by existing therapies, biosimilars, and upcoming entrants. Market entry barriers include manufacturing complexity, stringent regulatory approval, and pricing strategies designed to recoup R&D investments.
2. Current Market Size and Growth Trends
The global biologic market was valued at approximately USD 300 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of about 8-10% through 2030[1]. For niche indications, regional markets like the U.S. present premiums owing to reimbursement policies and high prevalence rates.
The demand for innovative therapies, accelerated approval pathways, and expanding indications amplify growth prospects. Market size considerations for drugs like NDC 62135-0460 depend on the specific indication, geographic reach, and payer access.
3. Competitive Dynamics
Market competitors include originator biologics, biosimilars, and emerging therapies. Biosimilar entry often exerts downward pressure on prices; however, patent protections, data exclusivity, and manufacturing intricacies sustain high prices for branded biologics.
In the U.S., Medicare and private insurers employ formulary negotiations and preferred drug listings, further influencing retail prices. International markets may exhibit different pricing landscapes, often reflecting local healthcare policies and economic conditions.
4. Reimbursement and Market Access
Reimbursement policies substantially influence the product’s market penetration. The Centers for Medicare & Medicaid Services (CMS) and private payers establish coverage criteria that can either facilitate or hinder uptake. Prior authorization and step therapy restrict or promote access, impacting revenue projections.
Market access strategies, including patient assistance programs and risk-sharing agreements, are key to optimizing demand and revenue streams.
Price Projections
1. Current Pricing Trends
As per recent data, biologics can be priced from USD 20,000 to over USD 100,000 annually per patient, depending on indication, dosage, and market. For example, oncology biologics often command prices exceeding USD 100,000, reflecting high development costs and clinical value[2].
Assuming NDC 62135-0460 pertains to a specialty biologic with demonstrated clinical efficacy, initial launch prices likely ranged between USD 50,000 and USD 90,000 per year. Pricing strategies often include list prices, discounts, and rebates negotiated with payers.
2. Factors Influencing Price Trajectories
-
Patent and Market Exclusivity: Patent life extensions or biosimilar entry timelines influence pricing stability. As patents expire, biosimilars typically reduce prices by 20-30% or more within a few years[3].
-
Regulatory Developments: New approvals or expanded indications can lead to price increases reflecting broader market opportunity.
-
Manufacturing and Supply Chain Costs: Complexity in biologic manufacturing sustains high prices; improvements or scale can pressure costs downward over time.
-
Market Penetration and Competition: Increased competition often results in tiered pricing, discounts, or value-based pricing arrangements.
3. Future Price Scenarios (Next 5 Years)
| Scenario | Approximate Price Range per Year | Key Drivers |
|---|---|---|
| Optimistic | USD 40,000 – USD 60,000 | Delayed biosimilar competition, market expansion, formulary protections |
| Moderate | USD 55,000 – USD 80,000 | Entry of biosimilars, price negotiations, increased demand |
| Pessimistic | USD 70,000 – USD 100,000+ | Limited biosimilar impact, high demand, supply constraints |
Note: These projections assume stable regulatory environments and no unexpected patent litigations or market disruptions.
4. Potential Impact of Biosimilars and Policy Changes
Biosimilars are expected to introduce competitive pricing by 2025–2027 for many biologics. The extent of price reduction depends on regional patent litigations, regulatory approvals, and payer acceptance. For biologics with direct biosimilar competition, price reductions of 20-40% are typical within three years of biosimilar market entry.
Policy reforms aimed at value-based pricing and transparency could further modify prices. The Affordable Care Act and subsequent legislation influence drug pricing dynamics, especially in the U.S.
Key Market Challenges
- High R&D and manufacturing costs, necessitating premium prices for recovery.
- Patent expirations and biosimilar entry, pressuring price erosion.
- Reimbursement hurdles and extensive payer negotiations affecting real-world prices.
- Regulatory uncertainties impacting launch timelines and market access.
Opportunities
- Expanding indications and geographic markets.
- Strategic collaborations to enhance manufacturing efficiencies.
- Innovative pricing models like outcome-based contracts.
- Accelerated approval pathways for orphan or rare disease indications, often commanding premium valuations.
Key Takeaways
- The pharmaceutical market for drugs similar to NDC 62135-0460 is characterized by high demand for innovative biologics, with prices currently ranging broadly based on indication and market factors.
- The advent of biosimilars is a significant disruptor, likely leading to substantial price reductions within the next 3–5 years.
- Market expansion, regulatory shifts, and payer strategies will be pivotal in shaping future pricing and revenue opportunities.
- Strategic positioning—through indications expansion, geographic rollout, and value-based pricing—can optimize long-term profitability.
- Monitoring patent statuses, regulatory developments, and competitive entries is essential to refine pricing strategies and forecast revenue streams accurately.
FAQs
1. What is the typical price range for biologic drugs similar to those identified by NDC 62135-0460?
Biologic drugs on the market commonly range from USD 20,000 to over USD 100,000 annually per patient, depending on indication, dosage, and market factors.
2. How will biosimilar competition affect the pricing of this drug?
Biosimilar entry generally leads to a 20-40% price reduction within three years post-approval, intensifying market competition and potentially lowering overall drug prices.
3. What regulatory factors could influence future price projections?
Patent expiries, approval of new indications, and changes in reimbursement policies are critical regulatory factors directly impacting drug pricing strategies.
4. Which markets present the highest revenue potential for this drug?
The United States and European Union remain the highest revenue-generating markets due to healthcare infrastructure, reimbursement systems, and demand for advanced therapies.
5. How do reimbursement policies impact the actual prices paid by patients and payers?
Reimbursement negotiations, discounts, rebates, and formulary placements influence end-user prices, often reducing the list price significantly through payer agreements.
References
[1] Grand View Research, "Biologics Market Size, Share & Trends Analysis," 2022.
[2] IMS Health (IQVIA), "The Global Use of Medicines in 2022," 2022.
[3] Food and Drug Administration (FDA), "Biosimilar and Interchangeable Products," 2023.
More… ↓
